| Outcome Measures: |
Primary: Safety and tolerability, as measured by the number, frequency and intensity of adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests, Up to Day 21 | Secondary: Maximum observed plasma concentration (Cmax) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Trough observed plasma concentration (Cmin) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Time of maximum observed plasma concentration (Tmax) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)] of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Accumulation Index following multiple dosing (AI) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Plasma half-life (T-HALF) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Percent urinary recovery (% UR) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Apparent total body clearance (CLT/F) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Renal clearance from plasma (CLR) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Peak to trough ratio (Cmax/Cmin) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Effective plasma half-life (T-HALFeff) of BMS-823778, as measured by plasma/urine concentration, Up to Day 21|Pharmacodynamics, as measured by Serum concentration of cortisol and cortisone after an oral dose of cortisone and biomarkers for HPA axis activity (urinary free cortisol and cortisone, salivary cortisol, ACTH, DHEA-S and 4-androstenedione), * HPA = Hypothalamic-pituitary-adrenal * DHEA-S = Dehydroepiandrosterone-sulphate * ACTH = adrenocorticotropic hormone, Up to Day 21
|
